A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF ETRASIMOD (PF-07915503) MINI TABLETS IN WATER AND 3 FOOD VEHICLES COMPARED TO THE ETRASIMOD (PF-07915503) CLINICAL IR TABLETS UNDER FASTED CONDITIONS, AND TO EVALUATE MINI TABLET PALATABILITY IN HEALTHY ADULT PARTICIPANTS
Latest Information Update: 12 Feb 2025
At a glance
- Drugs Etrasimod (Primary)
- Indications Alopecia areata; Atopic dermatitis; Crohn's disease; Eosinophilic oesophagitis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 29 Jan 2024 Status changed from active, no longer recruiting to completed.
- 01 Dec 2023 Planned End Date changed from 11 Jan 2024 to 2 Jan 2024.
- 01 Dec 2023 Planned primary completion date changed from 11 Jan 2024 to 2 Jan 2024.